Just reading the 2017 @ASCO @ASCO_pubs guideline on bone modifying agents for metastatic breast cancer highlights the limits of consensus opinions: No agreement on which of the 3 drugs to use, or whether zoledronic acid should be given every 12 weeks or every 3-4 weeks. 
That's kind of strange because denosumab costs 20 times more than the other two. That would have been an easy call for me. But it's listed first.
It looks like two groups could not agree with zoledronic acid should be given every 12 weeks or every 3-4 weeks so they put in both.
It looks like two groups could not agree with zoledronic acid should be given every 12 weeks or every 3-4 weeks so they put in both.
I stumbled on this as I'm reviewing a paper today. And it ties into the thread I posted yesterday.
https://twitter.com/vincentrk/status/1425581832838520833
This is not unique. Its common in consensus statements. In fact it was one of these that prompted redefinition of solitary plasmacytoma. Original definition said "Normal marrow & no M protein". But there was an asterisk which said: marrow maybe abnormal & M protein may be present
• • •
Missing some Tweet in this thread? You can try to
force a refresh
